Sg3 Management, LLC Bei Gene, Ltd. Put Options Transaction History

Sg3 Management, LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2022 May 16, 2022	SELL	$146.52 - $269.56 $1.47 Million - $2.7 Million	-10,000 Reduced 66.67%	5,000 $943,000
Q3 2021 Nov 15, 2021	BUY	$249.6 - $403.14 $3.74 Million - $6.05 Million	15,000 New	15,000 $5.45 Million
Q2 2021 Aug 16, 2021	SELL	$292.75 - $367.01 $6.88 Million - $8.62 Million	-23,500 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$260.64 - $382.12 $2.61 Million - $3.82 Million	10,000 Added 74.07%	23,500 $8.18 Million
Q4 2020 Feb 16, 2021	BUY	$221.31 - $316.61 $1.88 Million - $2.69 Million	8,500 Added 170.0%	13,500 $3.49 Million
Q3 2020 Nov 13, 2020	BUY	$189.18 - $286.44 $945,900 - $1.43 Million	5,000 New	5,000 $1.43 Million
Q1 2020 May 12, 2020	SELL	$121.84 - $173.19 $791,960 - $1.13 Million	-6,500 Closed	0 $0
Q4 2019 Feb 11, 2020	SELL	$115.78 - $208.34 $185,248 - $333,344	-1,600 Reduced 19.75%	6,500 $1.08 Million
Q3 2019 Nov 13, 2019	BUY	$120.61 - $148.29 $976,941 - $1.2 Million	8,100 New	8,100 $992,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.